Department of Pharmacology, School of Medicine of Ribeirão Preto, University of São Paulo, Brazil.
Auton Neurosci. 2011 Feb 24;160(1-2):90-8. doi: 10.1016/j.autneu.2010.11.002. Epub 2010 Dec 10.
The insular cortex (IC) has been reported to be involved in central cardiovascular control. In the present study, we investigated the cardiovascular responses evoked by microinjection of noradrenaline into the IC as well as the central and peripheral mechanisms involved in their mediation. Microinjection of noradrenaline into the IC (3, 7, 10, 15, 30 and 45 nmol/100 nL) caused long-lasting dose-related pressor and bradycardiac responses. The cardiovascular responses evoked by 15 nmol of noradrenaline were blocked by IC pretreatment with WB4101 or 5-methyl-urapidil, selective α(1)-adrenoceptor antagonists. IC pretreatment with either the selective α(2)-adrenoceptor antagonists RX821002 or the β-adrenoceptor antagonist propranolol did not affect noradrenaline cardiovascular responses. Noradrenaline cardiovascular responses were mimicked by microinjection of the selective α(1)-adrenoceptor agonist phenylephrine into the IC, thus reinforcing the idea that α(1)-adrenoceptors mediate cardiovascular responses to noradrenaline microinjected into the IC. The pressor response to noradrenaline microinjection was potentiated by i.v. pretreatment with the ganglion blocker pentolinium and inhibited by i.v. pretreatment with the selective V(1)-vasopressin receptor antagonist dTyr(CH(2))(5)(Me)AVP. The bradycardiac response to noradrenaline microinjection into the IC was abolished by pretreatment with either pentolinium or the V(1)-vasopressin receptor antagonist, indicating its reflex origin. In conclusion, our results suggest that pressor response evoked by microinjection of noradrenaline into the IC involve the activation of IC α(1)-adrenoceptors to cause the release of vasopressin into the circulation.
岛叶皮层(IC)已被报道参与中枢心血管控制。在本研究中,我们研究了微注射去甲肾上腺素到 IC 后引起的心血管反应,以及涉及它们介导的中枢和外周机制。微注射去甲肾上腺素到 IC(3、7、10、15、30 和 45 nmol/100 nL)引起与剂量相关的持久升压和心动过缓反应。用 WB4101 或 5-甲基-urapidil(选择性 α(1)-肾上腺素受体拮抗剂)预处理 IC 可阻断 15 nmol 去甲肾上腺素引起的心血管反应。用选择性 α(2)-肾上腺素受体拮抗剂 RX821002 或 β-肾上腺素受体拮抗剂普萘洛尔预处理 IC 并不影响去甲肾上腺素的心血管反应。微注射选择性 α(1)-肾上腺素受体激动剂苯肾上腺素到 IC 可模拟去甲肾上腺素的心血管反应,从而强化了 α(1)-肾上腺素受体介导去甲肾上腺素微注射到 IC 引起的心血管反应的观点。静脉预处理 ganglion 阻滞剂 pentolinium 可增强去甲肾上腺素微注射引起的升压反应,并抑制选择性 V(1)-血管加压素受体拮抗剂 dTyr(CH(2))(5)(Me)AVP 的静脉预处理。用 pentolinium 或 V(1)-血管加压素受体拮抗剂预处理可消除去甲肾上腺素微注射到 IC 引起的心动过缓反应,表明其反射起源。总之,我们的结果表明,微注射去甲肾上腺素到 IC 引起的升压反应涉及激活 IC α(1)-肾上腺素受体,导致血管加压素释放到循环中。